Evidence map›Paper›PMID 40071099›Full record

ArticleFrontiers in oncology2025

Data augmented lung cancer prediction framework using the nested case control NLST cohort.

Yifan Jiang, Venkata S K Manem

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yifan JiangCentre de Recherche du CHU de Québec, Université Laval, Québec, QC, Canada.
Venkata S K ManemCentre de Recherche du CHU de Québec, Université Laval, Québec, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: In the context of lung cancer screening, the scarcity of well-labeled medical images poses a significant challenge to implement supervised learning-based deep learning methods. While data augmentation is an effective technique for countering the difficulties caused by insufficient data, it has not been fully explored in the context of lung cancer screening. In this research study, we analyzed the state-of-the-art (SOTA) data augmentation techniques for lung cancer binary prediction. Methods: To comprehensively evaluate the efficiency of data augmentation approaches, we considered the nested case control National Lung Screening Trial (NLST) cohort comprising of 253 individuals who had the commonly used CT scans without contrast. The CT scans were pre-processed into three-dimensional volumes based on the lung nodule annotations. Subsequently, we evaluated five basic (online) and two generative model-based offline data augmentation methods with ten state-of-the-art (SOTA) 3D deep learning-based lung cancer prediction models. Results: Our results demonstrated that the performance improvement by data augmentation was highly dependent on approach used. The Cutmix method resulted in the highest average performance improvement across all three metrics: 1.07%, 3.29%, 1.19% for accuracy, F1 score and AUC, respectively. MobileNetV2 with a simple data augmentation approach achieved the best AUC of 0.8719 among all lung cancer predictors, demonstrating a 7.62% improvement compared to baseline. Furthermore, the MED-DDPM data augmentation approach was able to improve prediction performance by rebalancing the training set and adding moderately synthetic data. Conclusions: The effectiveness of online and offline data augmentation methods were highly sensitive to the prediction model, highlighting the importance of carefully selecting the optimal data augmentation method. Our findings suggest that certain traditional methods can provide more stable and higher performance compared to SOTA online data augmentation approaches. Overall, these results offer meaningful insights for the development and clinical integration of data augmented deep learning tools for lung cancer screening.

Indexed as

Artificial Intelliegncecancer risk predictioncomputed tomographydata augmentationlung cancermachine learning

Identifiers

PMID40071099
PMCPMC11893409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.